Advertisement
Advertisement
BNGO
Bionano Genomics, Inc. Common Stock
1.19
USDSponsored
+0.02
+1.71%
Apr 01, 15:59 UTC -4
Closed
After-Market
1.20
+0.01
+0.42%
BNGO Earnings Reports
Positive Surprise Ratio
BNGO beat 11 of 30 last estimates.
37%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$8.04M
/-$1.05
Implied change from Q4 25 (Revenue/ EPS)
+1.11%
/+3400.00%
Implied change from Q1 25 (Revenue/ EPS)
+24.50%
/-8.70%
Bionano Genomics, Inc. Common Stock earnings per share and revenue
On Mar 23, 2026, BNGO reported earnings of -0.03 USD per share (EPS) for Q4 25, beating the estimate of -1.42 USD, resulting in a 97.90% surprise. Revenue reached 7.95 million, compared to an expected 8.01 million, with a -0.74% difference. The market reacted with a -0.63% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -1.05 USD, with revenue projected to reach 8.04 million USD, implying an increase of 3400.00% EPS, and increase of 1.11% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
RenovoRx, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
INmune Bio Inc. Common stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%
PDS Biotechnology Corporation Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.14
Surprise
+27.76%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-17.65%
Lantern Pharma Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.36
Surprise
+23.27%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.29
Surprise
-7.72%
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.08
Surprise
-16.19%
Bicara Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.68
Actual
-$0.68
Surprise
+0.66%
Neumora Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.33
Actual
-$0.35
Surprise
-5.39%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.17
Surprise
+7.41%
FAQ
What were Bionano Genomics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Bionano Genomics, Inc. Common Stock reported EPS of -$0.03, beating estimates by 97.9%, and revenue of $7.95M, -0.74% below expectations.
How did the market react to Bionano Genomics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -0.63%, changed from $1.59 before the earnings release to $1.58 the day after.
When is Bionano Genomics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Bionano Genomics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Bionano Genomics, Inc. Common Stock is expected to report EPS of -$1.05 and revenue of $8.04M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement